Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 537-546

  Sasaki, Ayami ^a   Kamiyama, Toshiya ^a   Yokoo, Hideki ^a   Nakanishi, Kazuaki ^a   Kubota, Kanako ^b   Haga, Hironori ^b   Matsushita, Michiaki ^c   Ozaki, Michitaka ^c   Matsuno, Yoshihiro ^b   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CD133; Cytoplasmic expression; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CD133 ANTIGEN; SERUM ALBUMIN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TUMOR VOLUME; AGED; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; EVALUATION STUDY; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; SURVIVAL;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CYTOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954361859     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000890     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Takata M, Yamanaka N, Tanaka T, et al: What patients can survive disease free after complete resection for hepatocellular carcinoma? A multivariate analysis. Jpn J Clin Oncol 30: 75-81, 2000.
3. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507, 2000.
4. Ikeda K, Arase Y, Kobayashi M, et al: Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 38: 865-876, 2003.
5. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature 414: 105-111, 2001.
6. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squre J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
9. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
10. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
11. Ricci-Vitani L, Lombardi DG, Pilozzi E, Biffoni M, Torado M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
12. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
13. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758, 2008.
14. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
15. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824, 2006.
16. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450, 2007.
17. Song W, Li H, Tao K, et al: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcioma. Int J Clin Pract 62: 1212-1218, 2008.
18. Salnikov AV, Kusumawidjaja G, Rausch V, et al: Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic paramater. Cancer Lett 275: 185-193, 2008.
19. Liver Cancer Study Group of Japan. General Rules of the Clinical and Pathological Study of Primary Liver Cancer. 2nd edition. Kanehara & Co., Ltd., Tokyo, 2003.
20. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007.
21. Corbeil D, Röper K, Hellwig A, et al: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520, 2000.
22. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the stem cell marker CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48-62, 2008.
23. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S and Scanbia G: CD133 antigen expression in ovarian cancer. BMC Cancer 9: 221-230, 2009.
24. Corbeil D, Joester A, Fargeas C, et al: Expression of distinct splice variants of the stem cell marker prominin-1 (CD133) in glial cells. Glia 57: 860-874, 2009.
25. Yi JM, Tsai HC, Glöckner SC, et al: Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68: 8094-8103, 2008.
26. Maw MA, Corbeil D, Koch J, et al: A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 9: 27-34, 2000.
27. Begunot L, Lyall RM, Willingham MC and Pastan I: Downregulation of the epidermal growth factor receptor in KB cells is due to receptor internalizaiton and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 81: 2384-2388, 1984. (Pubitemid 14148263)
28. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC and Grizzle WE: Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8: 734-744, 2002. (Pubitemid 34742102)
29. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati PL and Pigato P: Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer 82: 1028-1036, 1998.
30. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K and Tsuneyoshi M: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 108: 768-775, 1995.
31. Shimozawa N and Hanazaki K: Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg 198: 356-365, 2004.
32. Shah SA, Wei AC, Cleary WS, et al: Prognosis and results after resection of very large (10 cm) hepatocellular carcinoma. J Gastrointest Surg 11: 589-595, 2007.
33. Kamiyama T, Nakanishi K, Yokoo H, et al: Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 16: 1560-1571, 2009.